null

null

null

null

null

null

null

null

null

Minimal debt; primarily equity-financed with ~$400M+ cash runway; leverage ratio near zero, making 20bp rate moves immaterial to interest expense

Low direct sensitivity; no significant floating-rate debt, but higher rates increase hurdle rate for biotech investors, pressuring valuation multiples

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) AAV/lentiviral vector CDMO capacity concentrated in US/EU; 2) specialized cell therapy raw materials (cytokines, plasmids) with limited Asian-sourced components

Minimal international revenue; pre-commercial stage company with no material foreign currency exposure; sovereign devaluation risk effectively null

Operations concentrated in Seattle, WA and South San Francisco, CA; no material international commercial presence; USD-denominated cost and revenue base

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or dual CDMOs for ex vivo and in vivo gene editing manufacturing; switching would require 12–24 months and significant regulatory revalidation

Clinical-stage biotech; cloud disruption would impair R&D data pipelines and informatics but not core therapeutic IP; recovery timeline ~30–60 days with migration

Secondary risk: bioinformatics and genomic data analysis platforms rely on cloud HPC; loss would delay trial data analysis and regulatory submissions

Moderate API coupling risk; genomic analysis workflows tied to cloud-native tools, but core IP (ZFN/gene editing) is proprietary and not cloud-vendor-dependent

Low Howey risk; revenue model is grant/collaboration-based not token or investment-contract driven; equity is conventional registered security

Very High

Moderate GDPR/CCPA exposure for clinical trial patient genomic data; handling of genetic data triggers heightened obligations under EU GDPR Article 9 sensitive data rules

Low current antitrust risk; pre-commercial, niche gene editing space; potential future scrutiny if platform dominates hemoglobinopathy or oncology gene therapy markets

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/non-recurring; revenue derived from collaboration agreements and grants; no subscription or recurring commercial product revenue as of 2024

Collaboration and licensing fees from pharma partners plus NIH/government grants; no product revenue yet; future model is drug sales and royalties

No commercial pricing architecture yet; future pricing will benchmark against gene therapy precedents (~$1.5M–$3.5M per patient for curative therapies)

Potentially very high if therapies achieve functional cure status; one-time curative pricing model with limited payer negotiating leverage in rare disease indications

Projected 70–85% gross margin at commercial scale, typical for gene therapy biologics after COGS normalization, though initial launch margins may be lower

No free-rider leakage problem; proprietary gene editing platform (ZFN) is IP-protected; academic or competitor free-riding limited by patent estate

Headcount-linear at current R&D stage; doubling pipeline programs requires proportional scientific and clinical staff; manufacturing scale-out partially sublinear via CDMO leverage

High marginal cost currently; each new program requires dedicated IND-enabling studies, clinical teams, and CDMO slots; not a low-marginal-cost software-like model

null

At 10x scale (multiple approved products), CAC becomes irrelevant; patient identification and payer reimbursement infrastructure become binding constraints, not marketing spend

Weak direct network effects; platform benefits from internal data accumulation (genomic editing outcomes) improving ZFN design, but no user-to-user network dynamics

-85.4% Return on Assets (Negative equity)

Moderate-low resilience; burn-rate company dependent on capital markets and partner funding; recession tightens biotech funding and partner R&D budgets

Biopharmaceutical/pharma collaboration partners (e.g., Novo Nordisk partnership) representing majority of non-grant revenue; high concentration risk

Government and foundation grant funders (NIH, CIRM); secondary revenue stream but non-recurring and subject to federal budget cycles

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital being deployed into future-state infrastructure: in-house AAV manufacturing facility build-out signals reallocation from CDMO dependency to owned production capacity

0001770121

SANA